Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

NCT04216589 on ClinicalTrials.gov · last registry update 2024-10-01

A small phase 2 — 51 participants, against a typical 110. The sponsor logged completion for 16 March 2023. Primary outcome, as filed: Change (Absolute) in IHTG (%). semaglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sponsor type: Nih
Enrollment: 51
Started: 2021-02-19
Primary completion: 2023-03-16 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change (Absolute) in IHTG (%)

Conditions studied

HIV Infections · Non-Alcoholic Fatty Liver Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.